stockportfolio.pro
Halozyme Therapeutics, Inc. (HALO)
Healthcare · Biotechnology · NasdaqGS
Halozyme Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.69M | $316.61M | $151.86M | $195.99M | $267.59M | $443.31M | $660.12M | $829.25M | $1.02B | $1.40B |
| Gross profit | $113.48M | $285.46M | $141.73M | $150.45M | $224.23M | $361.90M | $520.81M | $636.89M | $855.91M | $1.17B |
| Net income | $-103.02M | $62.97M | $-80.33M | $-72.24M | $129.09M | $402.71M | $202.13M | $281.59M | $444.09M | $316.89M |
| Net margin | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
Source: Halozyme Therapeutics, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Halozyme Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HALO in your portfolio →
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s revenue?
Halozyme Therapeutics, Inc. (HALO) reported revenue of $1.40B for fiscal year 2025, up 37.6% from the prior year, according to its SEC filings.
Is Halozyme Therapeutics, Inc. profitable?
Yes. HALO earned net income of $316.89M in fiscal 2025, a net margin of 22.7%.
What is HALO's P/E ratio?
Halozyme Therapeutics, Inc. trades at a price-to-earnings ratio of about 24.9 based on the latest data in our nightly-refreshed cache.
How fast is Halozyme Therapeutics, Inc. growing?
HALO's revenue grew at roughly 39.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.